questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the clinical and cost effectiveness of first-line use of encorafenib in combination with cetuximab and chemotherapy for patients with BRAF V600E-mutant metastatic colorectal cancer; and whether he has set a timetable for consideration by the National Institute for Health and Care Excellence of this treatment approach for routine NHS use.
answerText: The BREAKWATER study is investigating encorafenib, a BRAF inhibitor, in combination with cetuximab and fluorouracil-based chemotherapy for the potential treatment of colorectal cancer. This regimen does not currently have a United Kingdom marketing author...
heading: Bowel Cancer: Medical Treatments